Rehovot, Israel, April 21, 2016 – Nucleix, an innovative epigenetic cancer detection and screening company, announced today that Dr. Heiner Dreismann, a seasoned executive and industry expert, has joined the company?s board of directors.
?As the previous CEO of Roche Molecular, Heiner has remarkable knowledge of the diagnostic space, we are delighted that he is joining Nucleix?s board of directors,? said Elon Ganor, CEO and Chairman of Nucleix Ltd. ?Heiner?s experience in leading companies to major commercial success will assist us in creating significant corporate value and advance partnerships with major players in the industry.?
Dr. Dreismann has more than 30 years of experience in the health care industry, and is regarded as a pioneer in the early adoption of the polymerase chain reaction (PCR) technique, one of the most ubiquitous technologies in molecular biology and genetics research today. He had a successful career at the Roche Group from 1985 to 2006 where he held several senior positions, including President and CEO, Roche Molecular Systems, Head of Global Business Development, Roche Diagnostics and Member of Roche?s Global Diagnostic Executive Committee. Dr. Dreismann currently serves on the boards of several public and private health care companies. He earned a Master of Science degree in biology and his Doctor of Philosophy degree in microbiology/molecular biology (summa cum laude) from Westfaelische Wilhelms University (The University of Munster) in Germany.